1. Tauopathien
- Author
-
Gabor G. Kovacs, Johannes Levin, T. van Eimeren, Ulrich Müller, Sigrid C. Schwarz, Gesine Respondek, Thomas W. Rösler, Kerstin Schweyer, E. Höller, and G Höglinger
- Subjects
0301 basic medicine ,Movement disorders ,biology ,Imaging biomarker ,business.industry ,Tau protein ,General Medicine ,Disease ,medicine.disease ,Progressive supranuclear palsy ,03 medical and health sciences ,Psychiatry and Mental health ,030104 developmental biology ,0302 clinical medicine ,Neurology ,Nerve cells ,medicine ,biology.protein ,Corticobasal degeneration ,Dementia ,Neurology (clinical) ,medicine.symptom ,business ,Neuroscience ,030217 neurology & neurosurgery - Abstract
BACKGROUND The microtubule-associated tau protein is the defining denominator of a group of neurodegenerative diseases termed tauopathies. OBJECTIVE Provide a timely state of the art review on recent scientific advances in the field of tauopathies. MATERIAL AND METHODS Systematic review of the literature from the past 10 years. RESULTS Tau proteins are increasingly being recognized as a highly variable protein, underlying and defining a spectrum of molecularly defined diseases, with a clinical spectrum ranging from dementia to hypokinetic movement disorders. Genetic variation at the tau locus can trigger disease or modify disease risk. Tau protein alterations can damage nerve cells and propagate pathologies through the brain. Thus, tau proteins may serve both as a serological and imaging biomarker. Tau proteins also provide a broad spectrum of rational therapeutic interventions to prevent disease progression. This knowledge has led to modern clinical trials. CONCLUSION The field of tauopathies is in a state of dynamic and rapid progress, requiring close interdisciplinary collaboration.
- Published
- 2018
- Full Text
- View/download PDF